{
    "nctId": "NCT01808573",
    "briefTitle": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting",
    "officialTitle": "A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)",
    "overallStatus": "COMPLETED",
    "conditions": "HER2+ Metastatic Breast Cancer (MBC)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 621,
    "primaryOutcomeMeasure": "Centrally Assessed Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged \u226518 years at signing of informed consent.\n* Histologically confirmed MBC, current stage IV.\n* Documented HER2 overexpression or gene-amplified tumor immunohistochemistry 3+ or 2+, with confirmatory fluorescence in situ hybridization (FISH) +.\n* Prior treatment with at least two (2) HER2-directed regimens for metastatic breast cancer.\n\nExclusion Criteria:\n\n* Received previous therapy with capecitabine, neratinib, lapatinib, or any other HER2 directed tyrosine kinase inhibitor.\n\nNote: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}